GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics

GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, announced it has closed on a Series A financing generating immediate proceeds of $157 million. The fund raise was led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, …

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics Read More »